Literature DB >> 2297869

Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.

J L Fleiss, J T Bigger, M McDermott, J P Miller, T Moon, A J Moss, D Oakes, L M Rolnitzky, T M Therneau.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2297869     DOI： 10.1161/01.cir.81.2.684

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

1.  Prognostic value of myocardial hypoperfusion indexes in patients with suspected or known coronary artery disease.

Authors:  M Petretta; A Cuocolo; A Carpinelli; E Nicolai; G Valva; V Bianchi; L Salemme; M Salvatore; D Bonaduce
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

2.  Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction.

Authors:  J F Hansen
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

3.  Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction-A New Endpoint from Old Clinical Trials.

Authors:  Jacek T Niedziela; Mariusz Gąsior
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.